Stockreport

ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer

ASLAN Pharmaceuticals Limited - American Depositary Shares  (ASLN) 
US:NASDAQ Investor Relations: ir.aslanpharma.com
PDF - The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4 [Read more]